The risks associated with the widespread use of telemedicine in oncology: Four cases and review of the literature. Issue 7 (18th August 2021)

• Record Type: Journal Article
• Authors: Panet, François; Tétreault‐Langlois, Marianne; Morin, Vincent; Sultanem, Khalil; Melnychuk, David; Panasci, Lawrence
• Is Part Of: Cancer reports. Volume 5:Issue 7(2022)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2021-08-18
• Subjects: COVID‐19 -- oncology -- telemedicine; Cancer -- Periodicals; 616.994005
• DOI: 10.1002/cnr2.1531
• Languages: English
• ISSNs: 2573-8348

Abstract

Abstract: Background: COVID‐19 changed the way we practice oncology in multiple ways. Because most cancer patients are comorbid or immunocompromised, we are trying as much as possible to reduce their risk of infection. Marginal just 2 years ago, telemedicine quickly became preeminent with the pandemic to reduce hospital exposure. However, using only virtual visits in oncology patients risk delaying cancer diagnosis or the identification of a complication. Case series: We present here four cases where a serious medical problem evident on physical exam was overlooked during a virtual visit. Two of our patients experienced a delay in cancer diagnosis thus putting them at risk of local or distant spread. The two others were established oncology patients where a serious medical complication was missed on a virtual visit. Conclusions: Now more than a year into the pandemic, telemedicine has clearly been a useful tool by limiting unnecessary hospital visits. Yet, as our cases illustrate, its use in oncology without clear boundary can undermine the quality of care. Now that effective vaccines are reducing the transmission and the severity of infection, most oncology patients can be evaluated by a real‐time visit.